CEL-SCI Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled.

Help employers find you! Check out all the jobs and post your resume.